SignalPoint Asset Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,379 shares of the company’s stock after selling 156 shares during the quarter. SignalPoint Asset Management LLC’s holdings in Johnson & Johnson were worth $1,626,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the third quarter worth about $27,000. FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $37,000. Tower View Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the period. Creative Capital Management Investments LLC lifted its holdings in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the period. Finally, VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $48,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of research firms recently commented on JNJ. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley decreased their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Raymond James lifted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $177.31.
Read Our Latest Stock Report on JNJ
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ opened at $158.17 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The business’s 50 day moving average price is $158.71 and its 200-day moving average price is $156.69. The firm has a market capitalization of $381.15 billion, a PE ratio of 11.45, a P/E/G ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business’s revenue was down 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.35 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 34.47%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.